Successful treatment of joint and fascial chronic graft-versus-host disease with baricitinib

Rheumatology (Oxford). 2021 Dec 24;61(1):e1-e3. doi: 10.1093/rheumatology/keab599.

Authors

Masaki Shimizu¹, Asami Shimbo², Masatoshi Takagi², Katsuhide Eguchi³, Masataka Ishimura³, Junichi Sugita⁴, Tomohiro Morio², Hirokazu Kanegane¹

Affiliations

¹ Department of Child Health and Development, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
² Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
³ Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
⁴ Division of Hematology, Hokkaido University Hospital, Sapporo, Japan.

PMID: 34302457
DOI: 10.1093/rheumatology/keab599

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Azetidines / therapeutic use*
Graft vs Host Disease / diagnostic imaging
Graft vs Host Disease / drug therapy*
Graft vs Host Disease / etiology
Hematopoietic Stem Cell Transplantation / adverse effects*
Humans
Joint Diseases / diagnostic imaging
Joint Diseases / drug therapy*
Joint Diseases / etiology
Magnetic Resonance Imaging
Male
Purines / therapeutic use*
Pyrazoles / therapeutic use*
Sulfonamides / therapeutic use*
Young Adult

Substances

Azetidines
Purines
Pyrazoles
Sulfonamides
baricitinib